Optain is a medical AI startup that uses retinal imaging to enable early disease detection and prevention. The company was launched in 2023 through a collaboration between healthcare organizations Aegis Ventures and Northwell Holdings.
The company has developed an AI-powered platform and device that analyzes retinal scans from a portable camera to screen for over 140 eye and systemic conditions and systemic diseases like cardiovascular and neurological ones and diabetes. This non-invasive approach allows real-time risk assessment and early intervention. The technology is clinically validated and approved in several global markets. The company claims that its technology has gone through rigorous AI model training on a dataset of over 200,000 images, validated through peer review, and recognized in academic journals. Optain had aims to make the platform widely available in the US, starting with flagship customer Northwell Health.
Key customers and partnerships
The company has collaborated with researchers, clinicians, and industry partners such as Northwell Health, Aegis, and Ascertain.
Funding and financials
In May 2023, the company raised USD 12 million in seed funding, including an investment from Ascertain. The funds were earmarked to grow its operation and support its R&D while pursuing regulatory approval and commercial rollout processes.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.